Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 8, 2012, Pages 3143-3148

  Wei, Wei ^a   Dutchak, Paul A ^a,b   Wang, Xunde ^a   Ding, Xunshan ^a,b   Wang, Xueqian ^a   Bookout, Angie L ^a,b   Goetz, Regina ^c   Mohammadi, Moosa ^c   Gerard, Robert D ^a,b   Dechow, Paul C ^d   Mangelsdorf, David J ^a,b   Kliewer, Steven A ^a,b   Wan, Yihong ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

Adipocyte; Bone metabolism; Nuclear receptor; Osteoblast; Thiazolidinediones

Indexed keywords

FIBROBLAST GROWTH FACTOR 21; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE METABOLISM; ENERGY METABOLISM; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; LYMPHOCYTE TRANSFORMATION; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION;

ADIPOGENESIS; ANIMALS; BONE AND BONES; BONE MARROW; BONE RESORPTION; DRUG RESISTANCE; FIBROBLAST GROWTH FACTORS; HUMANS; MICE; MICE, KNOCKOUT; ORGAN SIZE; OSTEOBLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PPAR GAMMA; RANK LIGAND; THIAZOLIDINEDIONES;

EID: 84863116228     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1200797109     Document Type: Article

References (45)

1. Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916.
2. Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: Now and the future. Lancet 377:1276-1287.
3. Zaidi M (2007) Skeletal remodeling in health and disease. Nat Med 13:791-801.
4. Akune T, et al. (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855. (Pubitemid 38544143)
5. Karsenty G, Kronenberg HM, Settembre C (2009) Genetic control of bone formation. Annu Rev Cell Dev Biol 25:629-648.
6. Kawai M, Rosen CJ (2010) PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol 6:629-636.
7. Lazarenko OP, et al. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669-2680. (Pubitemid 46984815)
8. Pittenger MF, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147. (Pubitemid 29282067)
9. Novack DV, Teitelbaum SL (2008) The osteoclast: Friend or foe? Annu Rev Pathol 3: 457-484. (Pubitemid 351488289)
10. Goetz R, et al. (2007) Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 27: 3417-3428. (Pubitemid 46685217)
11. Itoh N, Ornitz DM (2008) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237:18-27.
12. Badman MK, et al. (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426-437. (Pubitemid 46825495)
13. Inagaki T, et al. (2007) Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 5:415-425. (Pubitemid 46825496)
14. Lundåsen T, et al. (2007) PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun 360:437-440. (Pubitemid 47039157)
15. Dutchak PA, et al. (2012) Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell, 10.1016/j.cell.2011.11.062.
16. Muise ES, et al. (2008) Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol Pharmacol 74:403-412.
17. Wang H, Qiang L, Farmer SR (2008) Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. Mol Cell Biol 28:188-200.
18. Zhang X, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253.
19. Berglund ED, et al. (2009) Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 150:4084-4093.
20. Coskun T, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149:6018-6027.
21. Kharitonenkov A, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635. (Pubitemid 40814671)
22. Kharitonenkov A, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148:774-781. (Pubitemid 46143178)
23. Xu J, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259.
24. Grey A (2009) Thiazolidinedione-induced skeletal fragility-mechanisms and implications. Diabetes Obes Metab 11:275-284.
25. Strotmeyer ES, Cauley JA (2007) Diabetes mellitus, bone mineral density, and fracture risk. Curr Opin Endocrinol Diabetes Obes 14:429-435. (Pubitemid 350059352)
26. Home PD, et al.; RECORD Study Team (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135.
27. Kahn SE, et al.; ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443. (Pubitemid 44903747)
28. Kahn SE, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group (2008) Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT). Diabetes Care 31:845-851.
29. Zinman B, et al.; ADOPT Study Group (2010) Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 95:134-142.
30. Inagaki T, et al. (2008) Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 8:77-83.
31. Potthoff MJ, et al. (2009) FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 106:10853-10858.
32. Nakashima T, et al. (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17:1231-1234.
33. Xiong J, et al. (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17:1235-1241.
34. Ali AA, et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-1235. (Pubitemid 40289310)
35. Li M, et al. (2006) Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 39:796-806. (Pubitemid 44311719)
36. Sottile V, Seuwen K, Kneissel M (2004) Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75:329-337. (Pubitemid 40064235)
37. Wan Y (2010) PPARγ in bone homeostasis. Trends Endocrinol Metab 21:722-728.
38. Wan Y, Chong LW, Evans RM (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13:1496-1503.
39. Wei W, et al. (2010) PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11:503-516.
40. ADHR Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348.
41. Shimada T, et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitaminD metabolism. J Clin Invest 113:561-568. (Pubitemid 38542505)
42. Wan Y, et al. (2007) Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev 21:1895-1908. (Pubitemid 47204929)
43. Wei W, et al. (2011) Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol Cell Biol 31:4706-4719.
44. Wei W, et al. (2011) Osteoclast progenitors reside in the peroxisome proliferator-activated receptor γ-expressing bone marrow cell population. Mol Cell Biol 31: 4692-4705.
45. Krum SA, et al. (2008) Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 27:535-545. (Pubitemid 351225684)